Article Text

PDF
Expectations regarding cognitive enhancement create substantial challenges
  1. E Racine1,
  2. C Forlini2
  1. 1
    Neuroethics Research Unit, Institut de recherches cliniques de Montréal, Department of Medicine and Department of Social and Preventive Medicine, Université de Montréal, and Department of Neurology and Neurosurgery & Biomedical Ethics Unit, McGill University, Montréal, Canada
  2. 2
    Neuroethics Research Unit, Institut de recherches cliniques de Montréal, Montréal, Canada
  1. Eric Racine, Neuroethics Research Unit, IRCM, 110 avenue des Pins Ouest, Montréal QC H2W lR7, Canada; eric.racine{at}ircm.qc.ca

Abstract

A recent discussion on cognitive enhancers has caused some controversy in the ethics and neuroscience fields by coming out in favour of making neuropharmaceuticals with enhancing properties available for general consumption. We highlight in this brief commentary why concerns regarding efficacy and safety, demands on resources, and public health are substantive enough to warrant serious reconsideration before pharmaceutical performance enhancement can be widely supported.

Statistics from Altmetric.com

Footnotes

  • Funding: Support for this publication comes from the Social Sciences and Humanities Research Council of Canada, the Canadian Institutes of Health Research and the Fonds de la recherche en santé du Québec.

  • Competing interests: None declared.

  • Provenance and peer review: Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • The concise argument
    Søren Holm